Trial Profile

Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ION 582 (Primary)
Indications Angelman syndrome
Focus Registrational; Therapeutic Use
Acronyms REVEAL
Sponsors Ionis Pharmaceuticals

Most Recent Events

09 Apr 2025 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT06914609).
09 Apr 2025 Status changed from planning to not yet recruiting.
19 Feb 2025 According to an Ionis Pharmaceuticals media release, company is on track to start this study in the first half of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com